line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,MONOPHARMA.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.304062,MONOPHARMA.NS
Normalized EBITDA,2025-03-31 00:00:00,86171000.0,MONOPHARMA.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,MONOPHARMA.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,30902000.0,MONOPHARMA.NS
Reconciled Depreciation,2025-03-31 00:00:00,1287000.0,MONOPHARMA.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,1523178000.0,MONOPHARMA.NS
EBITDA,2025-03-31 00:00:00,86171000.0,MONOPHARMA.NS
EBIT,2025-03-31 00:00:00,84884000.0,MONOPHARMA.NS
Net Interest Income,2025-03-31 00:00:00,-40255000.0,MONOPHARMA.NS
Interest Expense,2025-03-31 00:00:00,40255000.0,MONOPHARMA.NS
Interest Income,2025-03-31 00:00:00,,MONOPHARMA.NS
Normalized Income,2025-03-31 00:00:00,30902000.0,MONOPHARMA.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,30902000.0,MONOPHARMA.NS
Total Expenses,2025-03-31 00:00:00,1608354000.0,MONOPHARMA.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,MONOPHARMA.NS
Diluted Average Shares,2025-03-31 00:00:00,,MONOPHARMA.NS
Basic Average Shares,2025-03-31 00:00:00,,MONOPHARMA.NS
Diluted EPS,2025-03-31 00:00:00,,MONOPHARMA.NS
Basic EPS,2025-03-31 00:00:00,,MONOPHARMA.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,30902000.0,MONOPHARMA.NS
Net Income Common Stockholders,2025-03-31 00:00:00,30902000.0,MONOPHARMA.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income,2025-03-31 00:00:00,30902000.0,MONOPHARMA.NS
Minority Interests,2025-03-31 00:00:00,-157000.0,MONOPHARMA.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,31059000.0,MONOPHARMA.NS
Net Income Continuous Operations,2025-03-31 00:00:00,31059000.0,MONOPHARMA.NS
Tax Provision,2025-03-31 00:00:00,13570000.0,MONOPHARMA.NS
Pretax Income,2025-03-31 00:00:00,44629000.0,MONOPHARMA.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,9788000.0,MONOPHARMA.NS
Special Income Charges,2025-03-31 00:00:00,0.0,MONOPHARMA.NS
Write Off,2025-03-31 00:00:00,,MONOPHARMA.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-40255000.0,MONOPHARMA.NS
Total Other Finance Cost,2025-03-31 00:00:00,,MONOPHARMA.NS
Interest Expense Non Operating,2025-03-31 00:00:00,40255000.0,MONOPHARMA.NS
Interest Income Non Operating,2025-03-31 00:00:00,,MONOPHARMA.NS
Operating Income,2025-03-31 00:00:00,75095000.0,MONOPHARMA.NS
Operating Expense,2025-03-31 00:00:00,85176000.0,MONOPHARMA.NS
Other Operating Expenses,2025-03-31 00:00:00,46022000.0,MONOPHARMA.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,1287000.0,MONOPHARMA.NS
Depreciation Income Statement,2025-03-31 00:00:00,1287000.0,MONOPHARMA.NS
Selling General And Administration,2025-03-31 00:00:00,,MONOPHARMA.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,MONOPHARMA.NS
General And Administrative Expense,2025-03-31 00:00:00,,MONOPHARMA.NS
Rent And Landing Fees,2025-03-31 00:00:00,,MONOPHARMA.NS
Gross Profit,2025-03-31 00:00:00,160271000.0,MONOPHARMA.NS
Cost Of Revenue,2025-03-31 00:00:00,1523178000.0,MONOPHARMA.NS
Total Revenue,2025-03-31 00:00:00,1683449000.0,MONOPHARMA.NS
Operating Revenue,2025-03-31 00:00:00,1683449000.0,MONOPHARMA.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,MONOPHARMA.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.237818,MONOPHARMA.NS
Normalized EBITDA,2024-03-31 00:00:00,64241000.0,MONOPHARMA.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,MONOPHARMA.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,24513000.0,MONOPHARMA.NS
Reconciled Depreciation,2024-03-31 00:00:00,1152000.0,MONOPHARMA.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,1106760000.0,MONOPHARMA.NS
EBITDA,2024-03-31 00:00:00,64241000.0,MONOPHARMA.NS
EBIT,2024-03-31 00:00:00,63089000.0,MONOPHARMA.NS
Net Interest Income,2024-03-31 00:00:00,-30829000.0,MONOPHARMA.NS
Interest Expense,2024-03-31 00:00:00,30829000.0,MONOPHARMA.NS
Interest Income,2024-03-31 00:00:00,258000.0,MONOPHARMA.NS
Normalized Income,2024-03-31 00:00:00,24513000.0,MONOPHARMA.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,24513000.0,MONOPHARMA.NS
Total Expenses,2024-03-31 00:00:00,1161266000.0,MONOPHARMA.NS
Rent Expense Supplemental,2024-03-31 00:00:00,1607000.0,MONOPHARMA.NS
Diluted Average Shares,2024-03-31 00:00:00,15514557.0,MONOPHARMA.NS
Basic Average Shares,2024-03-31 00:00:00,15514557.0,MONOPHARMA.NS
Diluted EPS,2024-03-31 00:00:00,1.58,MONOPHARMA.NS
Basic EPS,2024-03-31 00:00:00,1.58,MONOPHARMA.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,24513000.0,MONOPHARMA.NS
Net Income Common Stockholders,2024-03-31 00:00:00,24513000.0,MONOPHARMA.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income,2024-03-31 00:00:00,24513000.0,MONOPHARMA.NS
Minority Interests,2024-03-31 00:00:00,-75000.0,MONOPHARMA.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,24588000.0,MONOPHARMA.NS
Net Income Continuous Operations,2024-03-31 00:00:00,24588000.0,MONOPHARMA.NS
Tax Provision,2024-03-31 00:00:00,7672000.0,MONOPHARMA.NS
Pretax Income,2024-03-31 00:00:00,32260000.0,MONOPHARMA.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,954000.0,MONOPHARMA.NS
Special Income Charges,2024-03-31 00:00:00,0.0,MONOPHARMA.NS
Write Off,2024-03-31 00:00:00,1897000.0,MONOPHARMA.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-30829000.0,MONOPHARMA.NS
Total Other Finance Cost,2024-03-31 00:00:00,2363000.0,MONOPHARMA.NS
Interest Expense Non Operating,2024-03-31 00:00:00,30829000.0,MONOPHARMA.NS
Interest Income Non Operating,2024-03-31 00:00:00,258000.0,MONOPHARMA.NS
Operating Income,2024-03-31 00:00:00,62136000.0,MONOPHARMA.NS
Operating Expense,2024-03-31 00:00:00,54506000.0,MONOPHARMA.NS
Other Operating Expenses,2024-03-31 00:00:00,18215000.0,MONOPHARMA.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,1152000.0,MONOPHARMA.NS
Depreciation Income Statement,2024-03-31 00:00:00,1152000.0,MONOPHARMA.NS
Selling General And Administration,2024-03-31 00:00:00,6889000.0,MONOPHARMA.NS
Selling And Marketing Expense,2024-03-31 00:00:00,4305000.0,MONOPHARMA.NS
General And Administrative Expense,2024-03-31 00:00:00,2584000.0,MONOPHARMA.NS
Rent And Landing Fees,2024-03-31 00:00:00,1607000.0,MONOPHARMA.NS
Gross Profit,2024-03-31 00:00:00,116642000.0,MONOPHARMA.NS
Cost Of Revenue,2024-03-31 00:00:00,1106760000.0,MONOPHARMA.NS
Total Revenue,2024-03-31 00:00:00,1223402000.0,MONOPHARMA.NS
Operating Revenue,2024-03-31 00:00:00,1223402000.0,MONOPHARMA.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,0.0,MONOPHARMA.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.264034,MONOPHARMA.NS
Normalized EBITDA,2023-03-31 00:00:00,31025000.0,MONOPHARMA.NS
Total Unusual Items,2023-03-31 00:00:00,0.0,MONOPHARMA.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,12320000.0,MONOPHARMA.NS
Reconciled Depreciation,2023-03-31 00:00:00,474000.0,MONOPHARMA.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,533379000.0,MONOPHARMA.NS
EBITDA,2023-03-31 00:00:00,31025000.0,MONOPHARMA.NS
EBIT,2023-03-31 00:00:00,29988000.0,MONOPHARMA.NS
Net Interest Income,2023-03-31 00:00:00,-13225000.0,MONOPHARMA.NS
Interest Expense,2023-03-31 00:00:00,13225000.0,MONOPHARMA.NS
Interest Income,2023-03-31 00:00:00,26000.0,MONOPHARMA.NS
Normalized Income,2023-03-31 00:00:00,12320000.0,MONOPHARMA.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,12320000.0,MONOPHARMA.NS
Total Expenses,2023-03-31 00:00:00,556144000.0,MONOPHARMA.NS
Rent Expense Supplemental,2023-03-31 00:00:00,1053000.0,MONOPHARMA.NS
Diluted Average Shares,2023-03-31 00:00:00,17668564.0,MONOPHARMA.NS
Basic Average Shares,2023-03-31 00:00:00,17668564.0,MONOPHARMA.NS
Diluted EPS,2023-03-31 00:00:00,0.697284,MONOPHARMA.NS
Basic EPS,2023-03-31 00:00:00,0.697284,MONOPHARMA.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,12320000.0,MONOPHARMA.NS
Net Income Common Stockholders,2023-03-31 00:00:00,12320000.0,MONOPHARMA.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income,2023-03-31 00:00:00,12320000.0,MONOPHARMA.NS
Minority Interests,2023-03-31 00:00:00,-17000.0,MONOPHARMA.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,12337000.0,MONOPHARMA.NS
Net Income Continuous Operations,2023-03-31 00:00:00,12337000.0,MONOPHARMA.NS
Tax Provision,2023-03-31 00:00:00,4426000.0,MONOPHARMA.NS
Pretax Income,2023-03-31 00:00:00,16763000.0,MONOPHARMA.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,1368000.0,MONOPHARMA.NS
Special Income Charges,2023-03-31 00:00:00,0.0,MONOPHARMA.NS
Write Off,2023-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-13225000.0,MONOPHARMA.NS
Total Other Finance Cost,2023-03-31 00:00:00,1055000.0,MONOPHARMA.NS
Interest Expense Non Operating,2023-03-31 00:00:00,13225000.0,MONOPHARMA.NS
Interest Income Non Operating,2023-03-31 00:00:00,26000.0,MONOPHARMA.NS
Operating Income,2023-03-31 00:00:00,28620000.0,MONOPHARMA.NS
Operating Expense,2023-03-31 00:00:00,22765000.0,MONOPHARMA.NS
Other Operating Expenses,2023-03-31 00:00:00,10688000.0,MONOPHARMA.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,1037000.0,MONOPHARMA.NS
Depreciation Income Statement,2023-03-31 00:00:00,1037000.0,MONOPHARMA.NS
Selling General And Administration,2023-03-31 00:00:00,1872000.0,MONOPHARMA.NS
Selling And Marketing Expense,2023-03-31 00:00:00,8000.0,MONOPHARMA.NS
General And Administrative Expense,2023-03-31 00:00:00,1864000.0,MONOPHARMA.NS
Rent And Landing Fees,2023-03-31 00:00:00,1053000.0,MONOPHARMA.NS
Gross Profit,2023-03-31 00:00:00,51385000.0,MONOPHARMA.NS
Cost Of Revenue,2023-03-31 00:00:00,533379000.0,MONOPHARMA.NS
Total Revenue,2023-03-31 00:00:00,584764000.0,MONOPHARMA.NS
Operating Revenue,2023-03-31 00:00:00,584764000.0,MONOPHARMA.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.363042,MONOPHARMA.NS
Normalized EBITDA,2022-03-31 00:00:00,13138000.0,MONOPHARMA.NS
Total Unusual Items,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Reconciled Depreciation,2022-03-31 00:00:00,1082000.0,MONOPHARMA.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,346914000.0,MONOPHARMA.NS
EBITDA,2022-03-31 00:00:00,13138000.0,MONOPHARMA.NS
EBIT,2022-03-31 00:00:00,12056000.0,MONOPHARMA.NS
Net Interest Income,2022-03-31 00:00:00,-7328000.0,MONOPHARMA.NS
Interest Expense,2022-03-31 00:00:00,6547000.0,MONOPHARMA.NS
Interest Income,2022-03-31 00:00:00,93000.0,MONOPHARMA.NS
Normalized Income,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Total Expenses,2022-03-31 00:00:00,358096000.0,MONOPHARMA.NS
Rent Expense Supplemental,2022-03-31 00:00:00,900000.0,MONOPHARMA.NS
Diluted Average Shares,2022-03-31 00:00:00,17668564.0,MONOPHARMA.NS
Basic Average Shares,2022-03-31 00:00:00,17668564.0,MONOPHARMA.NS
Diluted EPS,2022-03-31 00:00:00,0.198601,MONOPHARMA.NS
Basic EPS,2022-03-31 00:00:00,0.198601,MONOPHARMA.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Net Income Common Stockholders,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Minority Interests,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Net Income Continuous Operations,2022-03-31 00:00:00,3509000.0,MONOPHARMA.NS
Tax Provision,2022-03-31 00:00:00,2000000.0,MONOPHARMA.NS
Pretax Income,2022-03-31 00:00:00,5509000.0,MONOPHARMA.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,1104000.0,MONOPHARMA.NS
Special Income Charges,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Write Off,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-7328000.0,MONOPHARMA.NS
Total Other Finance Cost,2022-03-31 00:00:00,874000.0,MONOPHARMA.NS
Interest Expense Non Operating,2022-03-31 00:00:00,6547000.0,MONOPHARMA.NS
Interest Income Non Operating,2022-03-31 00:00:00,93000.0,MONOPHARMA.NS
Operating Income,2022-03-31 00:00:00,11734000.0,MONOPHARMA.NS
Operating Expense,2022-03-31 00:00:00,11182000.0,MONOPHARMA.NS
Other Operating Expenses,2022-03-31 00:00:00,2613000.0,MONOPHARMA.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,1082000.0,MONOPHARMA.NS
Depreciation Income Statement,2022-03-31 00:00:00,1082000.0,MONOPHARMA.NS
Selling General And Administration,2022-03-31 00:00:00,370000.0,MONOPHARMA.NS
Selling And Marketing Expense,2022-03-31 00:00:00,0.0,MONOPHARMA.NS
General And Administrative Expense,2022-03-31 00:00:00,370000.0,MONOPHARMA.NS
Rent And Landing Fees,2022-03-31 00:00:00,900000.0,MONOPHARMA.NS
Gross Profit,2022-03-31 00:00:00,22916000.0,MONOPHARMA.NS
Cost Of Revenue,2022-03-31 00:00:00,346914000.0,MONOPHARMA.NS
Total Revenue,2022-03-31 00:00:00,369830000.0,MONOPHARMA.NS
Operating Revenue,2022-03-31 00:00:00,369830000.0,MONOPHARMA.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,MONOPHARMA.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,MONOPHARMA.NS
Normalized EBITDA,2021-03-31 00:00:00,,MONOPHARMA.NS
Total Unusual Items,2021-03-31 00:00:00,,MONOPHARMA.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,MONOPHARMA.NS
Reconciled Depreciation,2021-03-31 00:00:00,,MONOPHARMA.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,MONOPHARMA.NS
EBITDA,2021-03-31 00:00:00,,MONOPHARMA.NS
EBIT,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Interest Income,2021-03-31 00:00:00,,MONOPHARMA.NS
Interest Expense,2021-03-31 00:00:00,,MONOPHARMA.NS
Interest Income,2021-03-31 00:00:00,0.0,MONOPHARMA.NS
Normalized Income,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,MONOPHARMA.NS
Total Expenses,2021-03-31 00:00:00,,MONOPHARMA.NS
Rent Expense Supplemental,2021-03-31 00:00:00,570000.0,MONOPHARMA.NS
Diluted Average Shares,2021-03-31 00:00:00,17668564.0,MONOPHARMA.NS
Basic Average Shares,2021-03-31 00:00:00,17668564.0,MONOPHARMA.NS
Diluted EPS,2021-03-31 00:00:00,0.053824,MONOPHARMA.NS
Basic EPS,2021-03-31 00:00:00,0.053824,MONOPHARMA.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,MONOPHARMA.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Income,2021-03-31 00:00:00,,MONOPHARMA.NS
Minority Interests,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,MONOPHARMA.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,MONOPHARMA.NS
Tax Provision,2021-03-31 00:00:00,,MONOPHARMA.NS
Pretax Income,2021-03-31 00:00:00,,MONOPHARMA.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,MONOPHARMA.NS
Special Income Charges,2021-03-31 00:00:00,,MONOPHARMA.NS
Write Off,2021-03-31 00:00:00,0.0,MONOPHARMA.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,MONOPHARMA.NS
Total Other Finance Cost,2021-03-31 00:00:00,171000.0,MONOPHARMA.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,MONOPHARMA.NS
Interest Income Non Operating,2021-03-31 00:00:00,0.0,MONOPHARMA.NS
Operating Income,2021-03-31 00:00:00,,MONOPHARMA.NS
Operating Expense,2021-03-31 00:00:00,,MONOPHARMA.NS
Other Operating Expenses,2021-03-31 00:00:00,,MONOPHARMA.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,MONOPHARMA.NS
Depreciation Income Statement,2021-03-31 00:00:00,,MONOPHARMA.NS
Selling General And Administration,2021-03-31 00:00:00,300000.0,MONOPHARMA.NS
Selling And Marketing Expense,2021-03-31 00:00:00,64000.0,MONOPHARMA.NS
General And Administrative Expense,2021-03-31 00:00:00,236000.0,MONOPHARMA.NS
Rent And Landing Fees,2021-03-31 00:00:00,570000.0,MONOPHARMA.NS
Gross Profit,2021-03-31 00:00:00,,MONOPHARMA.NS
Cost Of Revenue,2021-03-31 00:00:00,,MONOPHARMA.NS
Total Revenue,2021-03-31 00:00:00,,MONOPHARMA.NS
Operating Revenue,2021-03-31 00:00:00,,MONOPHARMA.NS
